Safety of Onabotulinumtoxin A in Chronic Migraine: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Authors
CORASANITI, Maria Tiziana
Bagetta, Giacinto

Nicotera, Pierluigi

Tarsitano, Assunta

Tonin, Paolo

Lawrence, Gary

SCUTERI, DAMIANA

SANDRINI, GIORGIO

Issue Date
2023-05-12Keywords
PRISMA 2020chronic migraine
onabotulinumtoxin A
SAFETY
treatment-related adverse events (TRAEs)
Metadata
Show full item recordJournal
ToxinsDOI
10.3390/toxins15050332PubMed ID
37235366PubMed Central ID
PMC10223125Item Type
ArticleOther
Language
enEISSN
2072-6651ae974a485f413a2113503eed53cd6c53
10.3390/toxins15050332
Scopus Count
Collections
The following license files are associated with this item:
- Creative Commons
Related articles
- Botulinum toxins for the prevention of migraine in adults.
- Authors: Herd CP, Tomlinson CL, Rick C, Scotton WJ, Edwards J, Ives N, Clarke CE, Sinclair A
- Issue date: 2018 Jun 25
- Randomized controlled studies evaluating Topiramate, Botulinum toxin type A, and mABs targeting CGRP in patients with chronic migraine and medication overuse headache: A systematic review and meta-analysis.
- Authors: Giri S, Tronvik E, Linde M, Pedersen SA, Hagen K
- Issue date: 2023 Apr
- Onabotulinumtoxin-A treatment in Greek patients with chronic migraine.
- Authors: Vikelis M, Argyriou AA, Dermitzakis EV, Spingos KC, Mitsikostas DD
- Issue date: 2016 Dec
- Treatment of chronic migraine with intramuscular pericranial injections of onabotulinumtoxin a.
- Authors: Belvis R, Mas N
- Issue date: 2014